<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00488826</url>
  </required_header>
  <id_info>
    <org_study_id>0887X-101518</org_study_id>
    <nct_id>NCT00488826</nct_id>
  </id_info>
  <brief_title>Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants</brief_title>
  <official_title>An Open-Label Controlled Phase I/III Study to Evaluate the Safety and Immunogenicity of Pneumococcal 7-Valent Conjugate Vaccine [DIPHTHERIA CRM197 PROTEIN] (PrevenarTM) in Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      This study is a combination of a Phase I and Phase III study design. The Phase I portion is
      an open-label, controlled study to evaluate the safety of 7vPnC in healthy Chinese infants.
      The Phase III portion is an open-label, controlled, randomized study to evaluate the safety
      and immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine (7vPnC)in healthy Chinese
      infants. Both phases include a Primary Series which includes the primary 3 doses of 7vPnC and
      /or Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP) at about 3, 4, and 5
      months of age; and a Booster Dose which includes the 4th dose of 7vPnC at 12-15 months of
      age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a combination of a Phase I and Phase III study design. The Phase I portion is
      an open-label, controlled study to evaluate the safety of 7vPnC in healthy Chinese infants.
      The Phase III portion is an open-label, controlled, randomized study to evaluate the safety
      and immunogenicity of 7vPnC in healthy Chinese infants. Both phases include a Primary Series
      which includes the primary 3 doses of 7vPnC and/or DTaP at about 3, 4, and 5 months of age;
      and a Booster Dose which includes the 4th dose of 7vPnC at 12-15 months of age. A total of
      822 healthy Chinese infants will be enrolled. The study will be conducted in 2 phases: Phase
      I and Phase III.

      Phase I: 22 healthy infants will be enrolled first and receive a dose of 7vPnC at least 7
      days prior to receiving DTaP and followed up on safety for 30 days post the immunization. If
      there are no adverse events of specific concern considered, in the opinion of the principal
      investigator, related to the study vaccine (including, though not limited to, infectious and
      allergic reactions as described in the China Immunization Handbook) within 4 days after the
      first dose immunization and no serious adverse event possibly, probably or definitely related
      to the study vaccine within 30 days after the first dose of immunization, Phase III can be
      initiated and the infants in Phase I will proceed to the next dose of the Primary Series. If
      such events occur, a medical review will be conducted by both the investigator and the
      Sponsor to decide if the study can proceed.

      Phase III: 800 infants will be enrolled and randomized to one of 3 groups according to the
      administration regimen. Group 1: 300 infants will receive the primary 3 doses of 7vPnC
      separately at 3, 4 and 5 months of age. Group 2: 300 infants will receive the primary 3 doses
      of 7vPnC concurrently with DTaP at 3, 4 and 5 months of age. Group 3: 200 infants will
      receive DTaP only at 3, 4 and 5 months of age. The injection site is the left upper arm
      deltoid for 7vPnC and the right upper arm deltoid for DTaP.

      Safety Evaluation: Each infant will have an initial physical examination and history obtained
      at the enrollment visit and a brief physical evaluation at each subsequent visit. Following
      immunization, each subject will be observed in the clinic for 30 minutes and evaluated for
      signs or symptoms of anaphylaxis and reactions at the injection sites. The parent or legal
      guardian will be required to take the infant's axillary temperature on the evening of
      immunization and for 3 consecutive evenings following the immunization. In addition, if the
      parent suspects that the infant may have a fever at any time in the four days following
      immunization, the temperature is to be taken and recorded. Thermometers for axillary
      temperature use and diary cards will be supplied by Wyeth for distribution to the parents.

      The parent or legal guardian of each subject will be instructed to complete a diary card for
      4 days [day of immunization (day 0) and next 3 days] following each immunization. Information
      collected will include: the subject's axillary temperature, local reactions at the 7vPnC
      injection site (All subjects in Phase I of the study and Group 1 and Group 2 of Phase III)
      and DTaP injection site (Group 2 and Group 3 of Phase III) (tenderness, presence and size of
      erythema and induration/swelling) and any systemic reactions (disrupted sleep, drowsiness,
      decreased appetite, irritability, vomiting, diarrhea and rash not limited to the injection
      site) occurring days 0-3. The subject will return to clinic or be visited at home on the day
      after immunization (Day 1) for local and systemic reaction observation by study personnel.
      The parent or legal guardian will be contacted by telephone or home visit at 2 and 3 days
      post-immunization to collect information on local and systemic events and the information
      will be recorded on the source data sheet by study personnel. On, or after, the fourth day
      after each immunization, the study personnel will collect the diary card. The data in the
      diary card will be reconciled with the data in the source data sheet. If there is
      discrepancy, it should be clarified with the parents and recorded.

      At the visit of next immunization, the interim medical history since Day 4 post last
      immunization will be reviewed with the parent/legal guardian. If there is any adverse event,
      it should be collected and recorded in the case report form. The primary source of data on
      adverse events will be the parent or legal guardian of each subject, as well as any medical
      records from a health care provider sought as a result of an adverse event. The parent/legal
      guardian is instructed to contact the investigators immediately for any serious adverse
      events.

      Assessment of Immunogenicity: Up to 3ml venous blood will be collected from 55 infants in
      Group 1, 55 infants in Group 2 and 55 infants in Group 3 of Phase III, immediately prior to
      the first dose and 30-40 days after the 3rd dose to assess the immunogenicity.

      Booster Dose: All infants in Phase I and Group 1 and Group 2 of Phase III will receive the
      booster dose of 7vPnC at 12-15 months of age. Local/systemic reactions will be observed in
      the same way as after the primary dose.

      Assessment of Immunogenicity: Up to 3ml venous blood will be collected from the same 55
      infants in Group 1 and 55 infants in Group 2 as in the Primary Series of Phase III,
      immediately prior to the forth dose and 30-40 days after the 4th dose to assess the
      immunogenicity.

      The statistical analysis of the two phases will be conducted separately. The statistical
      analysis of the primary series is planned when all subjects have received the 1st, 2nd and
      3rd dose of 7vPnC and 3 doses of DTaP or 3 doses of DTaP alone and the 30-day safety
      follow-up period has terminated. The analysis of the booster dose is planned when all
      subjects have received the 4th dose of 7vPnC and the 30-day safety follow-up period has
      terminated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Serotype-Specific IgG Antibodies</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of Serotype-Specific IgG Antibodies</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">800</enrollment>
  <condition>Pneumococcal Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7-valent pneumococcal conjugate vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese infants, aged 3-4 months (90-120 days) at enrollment, and have not received
             their 1st dose of DTaP

          -  In good health determined by medical history, physical examination (axillary
             temperature and weight) and clinical judgment of the investigator

          -  An informed consent form must be signed by at least one of the parent/legal guardian.
             The parent or legal guardian are willing to adhere to the regimen of the study and are
             capable of using the thermometer, calipers and filling out the diary card

        Exclusion Criteria:`

          -  Weight &lt; 2 SD for age

          -  History of neurological disorders including a personal and family history of
             convulsion and epilepsy (including febrile seizures)

          -  Receipt of blood products, including gamma globulin within 12 weeks prior to study
             entry

          -  Hypersensitivity to any component of 7vPnC, including diphtheria toxoid

          -  Known previous anaphylactic reactions to any vaccines or medicines

          -  Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection

          -  Known or suspected impairment of immune function due to the use of immunosuppressive
             therapy (including irradiation, corticosteroids, antimetabolites, alkylating agents,
             and cytotoxic agents), a genetic defect, HIV infection or other cause

          -  History of culture-proven invasive disease caused by S. pneumoniae

          -  Any significant congenital deformity or serious chronic diseases

          -  Previous immunization with licensed or investigational pneumococcal vaccine

          -  Other investigational medicine is being administered or has been administered within
             12 weeks before screening or participation in another investigational study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>90 Days</minimum_age>
    <maximum_age>120 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2007</study_first_submitted>
  <study_first_submitted_qc>June 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2007</study_first_posted>
  <results_first_submitted>March 31, 2009</results_first_submitted>
  <results_first_submitted_qc>March 31, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2009</results_first_posted>
  <last_update_submitted>January 15, 2010</last_update_submitted>
  <last_update_submitted_qc>January 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <keyword>Vaccines, Pneumococcal Conjugate Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited in China from September 2006 to May 2007.</recruitment_details>
      <pre_assignment_details>Subjects were enrolled into study according to inclusion/exclusion criteria without a screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>7vPnC Separately</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC) administered at 3, 4, and 5 months of age. Diphtheria and tetanus toxoids and accelular pertussis vaccine (DTaP) administered at least 7 days after 7vPnC at 3, 4, and 5 months of age.</description>
        </group>
        <group group_id="P2">
          <title>7vPnC + DTaP Concurrently</title>
          <description>7vPnC adminstered concurrently with DTaP at 3, 4, and 5 months of age.</description>
        </group>
        <group group_id="P3">
          <title>DTaP Alone</title>
          <description>DTaP administered at 3, 4, and 5 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="296"/>
                <participants group_id="P3" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="244"/>
                <participants group_id="P3" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviations</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>7vPnC Separately</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC) administered at 3, 4, and 5 months of age. Diphtheria and tetanus toxoids and accelular pertussis vaccine (DTaP) administered at least 7 days after 7vPnC at 3, 4, and 5 months of age.</description>
        </group>
        <group group_id="B2">
          <title>7vPnC + DTaP Concurrently</title>
          <description>7vPnC adminstered concurrently with DTaP at 3, 4, and 5 months of age.</description>
        </group>
        <group group_id="B3">
          <title>DTaP Alone</title>
          <description>DTaP administered at 3, 4, and 5 months of age.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="300"/>
            <count group_id="B2" value="296"/>
            <count group_id="B3" value="204"/>
            <count group_id="B4" value="800"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="1.0" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="B2" value="3.5" spread="1.0" lower_limit="3.0" upper_limit="4.0"/>
                    <measurement group_id="B3" value="3.5" spread="1.7" lower_limit="3.0" upper_limit="4.7"/>
                    <measurement group_id="B4" value="3.5" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Serotype-Specific IgG Antibodies</title>
        <description>Vaccine efficacy can be assessed by measuring the levels of antibodies to the specific types (or serotypes) of bacteria covered by the vaccine. IgG antibodies for the 7 pneumococcal serotypes in 7vPnC (4, 6B, 9V, 14, 18C, 19F, 23F) were assessed 30-50 days after the third dose of vaccine. Antibody levels were measured by standardized enzyme-linked immunosorbent assay (ELISA). The minimum level of antibodies required to confer protection has been defined as 0.15 ug/ml by the Northern California Kaiser Permanente (NCKP) study, and as 0.35 ug/ml by the World Health Organization (WHO).</description>
        <time_frame>7 months</time_frame>
        <population>Population analyzed was available immunogenicity population (all subjects who completed the primary series of 7vPnC or DTaP and had the post-third dose serum available for assessment) and were in either the &quot;7vPnC separately&quot; or &quot;DTaP alone&quot; group. The &quot;7vPnC + DTaP&quot; group was not part of the primary objective; no statistical testing was done.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC Separately</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) administered at 3, 4, and 5 months of age. Diphtheria and tetanus toxoids and accelular pertussis vaccine (DTaP) administered at least 7 days after 7vPnC at 3, 4, and 5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP Concurrently</title>
            <description>7vPnC adminstered concurrently with DTaP at 3, 4, and 5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>DTaP Alone</title>
            <description>DTaP administered at 3, 4, and 5 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Serotype-Specific IgG Antibodies</title>
          <description>Vaccine efficacy can be assessed by measuring the levels of antibodies to the specific types (or serotypes) of bacteria covered by the vaccine. IgG antibodies for the 7 pneumococcal serotypes in 7vPnC (4, 6B, 9V, 14, 18C, 19F, 23F) were assessed 30-50 days after the third dose of vaccine. Antibody levels were measured by standardized enzyme-linked immunosorbent assay (ELISA). The minimum level of antibodies required to confer protection has been defined as 0.15 ug/ml by the Northern California Kaiser Permanente (NCKP) study, and as 0.35 ug/ml by the World Health Organization (WHO).</description>
          <population>Population analyzed was available immunogenicity population (all subjects who completed the primary series of 7vPnC or DTaP and had the post-third dose serum available for assessment) and were in either the &quot;7vPnC separately&quot; or &quot;DTaP alone&quot; group. The &quot;7vPnC + DTaP&quot; group was not part of the primary objective; no statistical testing was done.</population>
          <units>ug/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.26" lower_limit="12.51" upper_limit="18.61"/>
                    <measurement group_id="O3" value="0.01" lower_limit="0.01" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="2.15" upper_limit="4.46"/>
                    <measurement group_id="O3" value="0.06" lower_limit="0.04" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" lower_limit="5.65" upper_limit="8.23"/>
                    <measurement group_id="O3" value="0.06" lower_limit="0.05" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.75" lower_limit="13.53" upper_limit="23.28"/>
                    <measurement group_id="O3" value="0.14" lower_limit="0.09" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" lower_limit="5.07" upper_limit="7.69"/>
                    <measurement group_id="O3" value="0.03" lower_limit="0.02" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.77" lower_limit="8.91" upper_limit="15.54"/>
                    <measurement group_id="O3" value="0.07" lower_limit="0.05" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.22" upper_limit="6.86"/>
                    <measurement group_id="O3" value="0.05" lower_limit="0.03" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC Separately&quot; group to the &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1097</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>793.6</ci_lower_limit>
            <ci_upper_limit>1461</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC Separately&quot; group to the &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>54.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>35.36</ci_lower_limit>
            <ci_upper_limit>85.49</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 6B.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC Separately&quot; group to the &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>99.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>79.81</ci_lower_limit>
            <ci_upper_limit>142.0</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 9V</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC Separately&quot; group to the &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>134.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>80.83</ci_lower_limit>
            <ci_upper_limit>197.1</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC Separately&quot; group to the &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>200.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>151.9</ci_lower_limit>
            <ci_upper_limit>302.4</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 18C.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC Separately&quot; group to the &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>181.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>119.8</ci_lower_limit>
            <ci_upper_limit>253.1</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 19F.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC Separately&quot; group to the &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>90.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>57.93</ci_lower_limit>
            <ci_upper_limit>150.5</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 23F.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Serotype-Specific IgG Antibodies</title>
        <description>Vaccine efficacy can be assessed by measuring the levels of antibodies to the specific types (or serotypes) of bacteria covered by the vaccine. IgG antibodies for the 7 pneumococcal serotypes in 7vPnC (4, 6B, 9V, 14, 18C, 19F, 23F) were assessed 30-50 days after the third dose of vaccine. Antibody levels were measured by standardized enzyme-linked immunosorbent assay (ELISA). The minimum level of antibodies required to confer protection has been defined as 0.15 ug/ml by the Northern California Kaiser Permanente (NCKP) study and as 0.35 ug/ml by the World Health Organization (WHO).</description>
        <time_frame>7 months</time_frame>
        <population>The population analyzed was all the available immunogenicity population (all subjects who completed the primary series of 7vPnC or DTaP and had the post third dose serum available for assessment) and were in either &quot;7vPnC+DTaP Concurrently&quot; or &quot;DTaP Alone&quot; group. The &quot;7vPnC Separately&quot; group was not included as part of this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>7vPnC Separately</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) administered at 3, 4, and 5 months of age. Diphtheria and tetanus toxoids and accelular pertussis vaccine (DTaP) administered at least 7 days after 7vPnC at 3, 4, and 5 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC + DTaP Concurrently</title>
            <description>7vPnC adminstered concurrently with DTaP at 3, 4, and 5 months of age.</description>
          </group>
          <group group_id="O3">
            <title>DTaP Alone</title>
            <description>DTaP administered at 3, 4, and 5 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Serotype-Specific IgG Antibodies</title>
          <description>Vaccine efficacy can be assessed by measuring the levels of antibodies to the specific types (or serotypes) of bacteria covered by the vaccine. IgG antibodies for the 7 pneumococcal serotypes in 7vPnC (4, 6B, 9V, 14, 18C, 19F, 23F) were assessed 30-50 days after the third dose of vaccine. Antibody levels were measured by standardized enzyme-linked immunosorbent assay (ELISA). The minimum level of antibodies required to confer protection has been defined as 0.15 ug/ml by the Northern California Kaiser Permanente (NCKP) study and as 0.35 ug/ml by the World Health Organization (WHO).</description>
          <population>The population analyzed was all the available immunogenicity population (all subjects who completed the primary series of 7vPnC or DTaP and had the post third dose serum available for assessment) and were in either &quot;7vPnC+DTaP Concurrently&quot; or &quot;DTaP Alone&quot; group. The &quot;7vPnC Separately&quot; group was not included as part of this objective.</population>
          <units>ug/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8.99" lower_limit="7.59" upper_limit="10.66"/>
                    <measurement group_id="O3" value="0.01" lower_limit="0.01" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.19" lower_limit="0.86" upper_limit="1.64"/>
                    <measurement group_id="O3" value="0.06" lower_limit="0.04" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.9" lower_limit="3.89" upper_limit="6.16"/>
                    <measurement group_id="O3" value="0.06" lower_limit="0.05" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="13.35" lower_limit="10.31" upper_limit="17.29"/>
                    <measurement group_id="O3" value="0.14" lower_limit="0.09" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.77" lower_limit="3.79" upper_limit="6.00"/>
                    <measurement group_id="O3" value="0.03" lower_limit="0.02" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5.62" lower_limit="4.45" upper_limit="7.09"/>
                    <measurement group_id="O3" value="0.07" lower_limit="0.05" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.27" lower_limit="1.68" upper_limit="3.06"/>
                    <measurement group_id="O3" value="0.05" lower_limit="0.03" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC + DTaP Concurrently&quot; group to &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>665.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>473.3</ci_lower_limit>
            <ci_upper_limit>851.2</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC + DTaP Concurrently&quot; group to &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>22.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>13.99</ci_lower_limit>
            <ci_upper_limit>31.77</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 6B.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC + DTaP Concurrently&quot; group to &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>73.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>56.41</ci_lower_limit>
            <ci_upper_limit>103.6</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 9V.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC + DTaP Concurrently&quot; group to &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>99.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>61.09</ci_lower_limit>
            <ci_upper_limit>147.5</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 14.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC + DTaP Concurrently&quot; group to &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>164</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>114.9</ci_lower_limit>
            <ci_upper_limit>232.9</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 18C.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC + DTaP Concurrently&quot; group to &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>81.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>57.98</ci_lower_limit>
            <ci_upper_limit>119.1</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 19F.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the &quot;7vPnC + DTaP Concurrently&quot; group to &quot;DTaP Alone&quot; group geometric mean comparisons (GMC) was provided with a corresponding 90% confidence interval.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>44.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>29.48</ci_lower_limit>
            <ci_upper_limit>68.71</ci_upper_limit>
            <estimate_desc>This analysis is for Serotype 23F.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>7vPnC Separately</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC) administered at 3, 4, and 5 months of age. Diphtheria and tetanus toxoids and accelular pertussis vaccine (DTaP) administered at least 7 days after 7vPnC at 3, 4, and 5 months of age.</description>
        </group>
        <group group_id="E2">
          <title>7vPnC + DTaP Concurrently</title>
          <description>7vPnC adminstered concurrently with DTaP at 3, 4, and 5 months of age.</description>
        </group>
        <group group_id="E3">
          <title>DTaP Alone</title>
          <description>DTaP administered at 3, 4, and 5 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
                <counts group_id="E2" subjects_affected="7"/>
                <counts group_id="E3" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Tachypnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Acute Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="206"/>
                <counts group_id="E2" subjects_affected="263"/>
                <counts group_id="E3" subjects_affected="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="297"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

